Article
Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification
Registro en:
BRAGA, Saulo Fehelberg Pinto et al. Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification. Bioorg Med Chem., v. 25, n. 6, p. 1889-1900, 2017
0968-0896
10.1016/j.bmc.2017.02.009
Autor
Braga, Saulo Fehelberg Pinto
Martins, Luan Carvalho
Silva, Elany Barbosa da
Sales Júnior, Policarpo Ademar
Murta, Silvane Maria Fonseca
Romanha, Alvaro José
Soh, Wai Tuck
Brandstetter, Hans
Ferreira, Rafaela Salgado
Oliveira, Renata Barbosa de
Resumen
Analogues of 8-chloro-N-(3-morpholinopropyl)-5H-pyrimido[5,4-b]indol-4-amine 1, a known cruzain inhibitor, were synthesized using a molecular simplification strategy. Five series of analogues were obtained: indole, pyrimidine, quinoline, aniline and pyrrole derivatives. The activity of the compounds was evaluated against the enzymes cruzain and rhodesain as well as against Trypanosoma cruzi amastigote and trypomastigote forms. The 4-aminoquinoline derivatives showed promising activity against both enzymes, with IC50 values ranging from 15 to 125 µM. These derivatives were selective inhibitors for the parasitic proteases, being unable to inhibit mammalian cathepsins B and S. The most active compound against cruzain (compound 5a; IC50 = 15 µM) is considerably more synthetically accessible than 1, while retaining its ligand efficiency. As observed for the original lead, compound 5a was shown to be a competitive enzyme inhibitor. In addition, it was also active against T. cruzi (IC50 = 67.7 µM). Interestingly, the pyrimidine derivative 4b, although inactive in enzymatic assays, was highly active against T. cruzi (IC50 = 3.1 µM) with remarkable selectivity index (SI = 128) compared to uninfected fibroblasts. Both 5a and 4b exhibit drug-like physicochemical properties and are predicted to have a favorable ADME profile, therefore having great potential as candidates for lead optimization in the search for new drugs to treat Chagas disease. 2022-01-01